ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2021

Abstract Number: 0794

Application of Treat to Target and Impact of Sustained Low Disease Activity or Remission on Function in Rheumatoid Arthritis Patients

Louis Bessette1, Edward Keystone2, Proton Rahman3, Keltie Anderson4, Emmanouil Rampakakis5, Allen Lehman6, Meagan Rachich6, Francois Nantel7 and Odalis Asin-Milan6, 1Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, 2Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 3Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, 4University of Saskatchewan, Saskatoon, SK, Canada, 5JSS Medical Research, Montréal, QC, Canada, 6Janssen Inc., Toronto, ON, Canada, 7., Montréal, QC, Canada

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2021

Keywords: registry, rheumatoid arthritis

Session Information

Date: Sunday, November 7, 2021

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: The aim of this analysis was to compare between enrolment periods RA treatment outcomes and frequency of treating to target, and to assess the impact of target type on long-term function.

Methods: This is a post-hoc analysis of data from the Biologic Treatment Registry Across Canada (BioTRAC). Patients with RA who initiated treatment with infliximab or subcutaneous golimumab were included. Patients were grouped into enrolment periods: 2002-2004, 2005-2008, 2009-2012, 2013-2015, 2016-2017. Achievement of LDA (CDAI LDA or SDAI LDA or SJC≤1), remission (CDAI remission or SDAI remission or SJC=0), and sustained LDA or remission (at 6 and 12 months) were compared between enrolment periods with the Chi-square test and multivariate logistic regression. The impact of achieving LDA or remission at 6 months, 12 months, or both (sustained) on HAQ-DI at 18 months was assessed with one-way ANOVA and generalized linear models.

Results: 1420 patients treated with anti-TNFs (IFX: n=890; GLM: n=530) were included. Over calendar time, a significant decrease in baseline disease duration and disease activity scores (CDAI, SDAI, SJC28, TJC28, HAQ) was observed (p < 0.001).

Across enrolment periods, significant differences were observed in target achievement with higher rates observed in more recent years. Upon adjusting for baseline CDAI and prior biologic exposure, no differences between enrolment periods were observed in achieving LDA, remission or sustained LDA/remission at 6 months; however, significantly (p=0.030) higher odds of achieving remission at 12 months were observed in more recent years.

Among patients not achieving LDA at 6 and 12 months, an intervention was applied in approximately 40% of patients, without significant differences between enrolment periods. Between 6 and 12 months, the most common intervention was anti-TNF discontinuation (64.9% of non-LDA achievers), followed by DMARD addition (9.8%), NSAID addition (8.8%), or steroid addition (7.2%). Similar results were obtained post 12 months.

Patients achieving sustained LDA, followed by those achieving LDA either at 6 or 12 months had significantly lower HAQ-DI at 18 months compared to patients not achieving LDA at either timepoint (0.8 vs. 1.1 vs. 1.4; p< 0.001). Similar results were observed when evaluating achievement of disease remission albeit with greater impact on HAQ-DI at 18 months (0.7 vs. 1.1 vs. 1.2; p< 0.001). Adjustment for baseline HAQ-DI did not impact the results.

Conclusion: Target achievement has increased over time although emphasis in treating to target may be placed in the first 6 months of treatment. Achieving stricter targets was associated with better long-term patient function.


Disclosures: L. Bessette, Amgen, 2, 5, 6, Bristol-Myers Squibb, 2, 5, 6, Janssen, 2, 5, 6, Roche, 2, 5, 6, UCB, 2, 5, 6, AbbVie, 2, 5, 6, Pfizer, 2, 5, 6, Merck & Co, 2, 5, Celgene, 2, 5, 6, Sanofi, 2, 5, 6, Eli Lilly, 2, 5, 6, Novartis, 2, 5, 6, Gilead, 2, 5, 6, Sandoz, 2, 5, 6, Teva, 2, 6; E. Keystone, AbbVie, 2, 6, Amgen, 2, 5, 6, Bristol-Myers Squibb Company, 2, Celltrion, 2, Gilead Sciences, 2, F. Hoffmann-La Roche, 2, 6, Janssen, 2, 6, Eli Lilly, 2, Merck, 2, 5, 6, Myriad Autoimmune, 2, Novartis, 6, Pfizer Inc, 2, 5, 6, PuraPharm, 5, Sandoz, 2, Sanofi-Genzyme, 2, 6, Samsung Bioepis, 2; P. Rahman, Janssen, 2, 5, 6, Novartis, 2, 5, 6, AbbVie, 2, 6, Amgen, 2, 6, Bristol Myers Squibb, 2, 6, Celgene, 2, 6, Eli Lilly, 2, 6, Pfizer, 2, 6, UCB, 2, 6, Merck, 2, 6; K. Anderson, None; E. Rampakakis, None; A. Lehman, Janssen Inc., 3; M. Rachich, Janssen, 3, 11; F. Nantel, None; O. Asin-Milan, Janssen, 3.

To cite this abstract in AMA style:

Bessette L, Keystone E, Rahman P, Anderson K, Rampakakis E, Lehman A, Rachich M, Nantel F, Asin-Milan O. Application of Treat to Target and Impact of Sustained Low Disease Activity or Remission on Function in Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/application-of-treat-to-target-and-impact-of-sustained-low-disease-activity-or-remission-on-function-in-rheumatoid-arthritis-patients/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/application-of-treat-to-target-and-impact-of-sustained-low-disease-activity-or-remission-on-function-in-rheumatoid-arthritis-patients/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology